Lundbeck EVP of commercial operations resigns

Board sets wheels in motion to find a replacement

Stig Løkke Pedersen, EVP for Commercial Operations at Danish pharmaceutical firm H. Lundbeck, has resigned in order to pursue new opportunities.

The board of directors of Lundbeck will now initiate a process to find a replacement.

Pedersen joined Lundbeck in January 1992 with responsibility for the company's business development activities. Following a period as managing director of Lundbeck Netherlands, he has since 1998 been part of the corporate senior management. He was appointed executive vice president in April 2003 and has held the position as EVP for commercial operations for the last six years.

You may also like

Media

Domain Therapeutics receives $125m to assign its intellectual property

Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by a French biotech
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Moving to continuous processes

As both the regulators and equipment manufacturers push the concept of continuous manufacturing, the mindset is filtering down from research and API production to finished products. But are all the requirements in place to make it successful? Susan Birks reports
Finance

Lundbeck embarks on another restructuring to drive profit and ensure growth

Will cut around 1,000 jobs in Europe
Media

Alzheimer’s treatment market value to exceed US$13bn by 2023

Rising prevalence, advances in diagnostic capability and greater awareness will drive growth
Finance

Lundbeck to buy Chelsea Therapeutics for US$658m

Danish company gains rights to FDA-approved Northera for the treatment of neurological disorders
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Finance

New products drive growth at Lundbeck in 2013

Received five approvals from US and European regulators
Subscribe now